Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
24.01.2023 13:23:33
|
Johnson & Johnson Q4 Profit Down 26%, But Adj. EPS Tops Estimates
(RTTNews) - Healthcare company Johnson & Johnson (JNJ) on Tuesday reported that profit for fourth quarter declined 25.9 percent from last year, reflecting a sales decline and higher provisions for income taxes.
Adjusted earnings per share topped analysts' expectations, while quarterly revenues missed it by a whisker. The company also initiated operational earnings forecast for the full-year 2023, above estimates.
For the fourth quarter, net earnings declined about 25 percent to $3.52 billion or $1.33 per share from $4.74 billion or $1.77 per share in the prior-year quarter.
Excluding items, adjusted net earnings for the quarter were $6.22 billion or $2.35 per share, compared to $5.68 billion or $2.13 per share in the year-ago quarter.
On average, 14 analysts polled by Thomson Reuters expected the company to report earnings of $2.23 per share for the quarter. Analysts' estimates typically exclude special items.
Sales for the quarter decreased 4.4 percent to $23.71 billion from $24.80 billion in the same quarter last year, primarily hurt by unfavorable foreign exchange and reduced COVID-19 vaccine sales. Analysts expected revenues of $23.94 billion for the quarter.
Operational sales, excluding COVID-19 Vaccine, grew 4.6 percent. Operational sales edged up 0.9 percent and adjusted operational sales edged up 0.8 percent.
Region-wise, US sales grew 2.9 percent to $12.52 billion, while international sales declined 11.5 percent to $11.19 billion from last year.
Consumer Health worldwide sales edged up 1 percent to $3.77 billion, while pharmaceutical worldwide sales declined 7.4 percent to $13.16 billion and medical devices worldwide sales decreased 1.2 percent to $6.78 billion from last year. Looking ahead to fiscal 2023, the company now projects adjusted earnings in a range of $10.45 to $10.65 per share and adjusted operational earnings in a range of $10.40 to $10.60 per share.
Additionally, the company now projects reported sales and operational sales between $96.9 billion and $97.9 billion, with adjusted operational sales growth of 3.5 to 4.5 percent. The Street is looking for earnings of $10.33 per share on a revenue growth of 2.9 percent to $97.84 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
16:03 |
Dow Jones-Handel aktuell: Dow Jones beginnt die Freitagssitzung im Minus (finanzen.at) | |
22.05.25 |
Optimismus in New York: Dow Jones präsentiert sich am Nachmittag fester (finanzen.at) | |
22.05.25 |
NYSE-Handel: Dow Jones mittags mit Gewinnen (finanzen.at) | |
21.05.25 |
Börse New York: Dow Jones verbucht zum Ende des Mittwochshandels Verluste (finanzen.at) | |
21.05.25 |
Schwacher Handel: Dow Jones gibt am Mittwochnachmittag nach (finanzen.at) | |
21.05.25 |
Dow Jones-Handel aktuell: Dow Jones in Rot (finanzen.at) | |
21.05.25 |
Handel in New York: Dow Jones startet mit Verlusten (finanzen.at) | |
20.05.25 |
Anleger in New York halten sich zurück: Dow Jones verbucht schlussendlich Verluste (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 134,50 | -0,66% |
|